Kirr Marbach & Co. LLC IN cut its stake in shares of Biogen Inc. (NASDAQ:BIIB - Free Report) by 13.3% during the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 29,798 shares of the biotechnology company's stock after selling 4,578 shares during the quarter. Kirr Marbach & Co. LLC IN's holdings in Biogen were worth $4,557,000 as of its most recent SEC filing.
A number of other institutional investors have also recently made changes to their positions in BIIB. State Street Corp boosted its position in Biogen by 3.5% during the third quarter. State Street Corp now owns 7,344,960 shares of the biotechnology company's stock valued at $1,423,747,000 after acquiring an additional 248,942 shares during the last quarter. Geode Capital Management LLC lifted its stake in shares of Biogen by 1.3% in the 3rd quarter. Geode Capital Management LLC now owns 3,613,020 shares of the biotechnology company's stock valued at $698,062,000 after purchasing an additional 47,055 shares during the period. Pacer Advisors Inc. boosted its position in shares of Biogen by 13,574.7% during the 4th quarter. Pacer Advisors Inc. now owns 2,667,531 shares of the biotechnology company's stock valued at $407,919,000 after purchasing an additional 2,648,024 shares in the last quarter. RA Capital Management L.P. grew its stake in Biogen by 20.6% during the third quarter. RA Capital Management L.P. now owns 1,184,456 shares of the biotechnology company's stock worth $229,595,000 after purchasing an additional 202,317 shares during the period. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC increased its holdings in Biogen by 1.7% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,152,691 shares of the biotechnology company's stock worth $223,438,000 after purchasing an additional 18,905 shares in the last quarter. Institutional investors own 87.93% of the company's stock.
Biogen Trading Down 0.7 %
Shares of NASDAQ:BIIB traded down $1.05 during midday trading on Wednesday, hitting $144.44. 662,544 shares of the stock traded hands, compared to its average volume of 1,242,267. The company has a quick ratio of 0.80, a current ratio of 1.26 and a debt-to-equity ratio of 0.28. The business's 50 day moving average is $151.55 and its two-hundred day moving average is $180.05. The stock has a market capitalization of $21.05 billion, a PE ratio of 13.05, a P/E/G ratio of 1.64 and a beta of -0.07. Biogen Inc. has a one year low of $139.71 and a one year high of $251.99.
Biogen (NASDAQ:BIIB - Get Free Report) last released its quarterly earnings results on Wednesday, October 30th. The biotechnology company reported $4.08 earnings per share for the quarter, beating the consensus estimate of $3.77 by $0.31. Biogen had a net margin of 16.81% and a return on equity of 14.98%. The business had revenue of $2.47 billion for the quarter, compared to analysts' expectations of $2.43 billion. During the same quarter in the previous year, the business posted $4.36 earnings per share. The firm's revenue for the quarter was down 2.5% compared to the same quarter last year. As a group, research analysts forecast that Biogen Inc. will post 16.41 earnings per share for the current year.
Analyst Ratings Changes
BIIB has been the topic of a number of research analyst reports. William Blair restated an "outperform" rating on shares of Biogen in a report on Monday, January 13th. Royal Bank of Canada dropped their price objective on shares of Biogen from $292.00 to $269.00 and set an "outperform" rating on the stock in a report on Friday, October 4th. Truist Financial dropped their price target on Biogen from $302.00 to $220.00 and set a "buy" rating on the stock in a research note on Wednesday, January 8th. Needham & Company LLC cut Biogen from a "buy" rating to a "hold" rating and set a $270.00 price objective for the company. in a research note on Monday, November 18th. Finally, Wells Fargo & Company lowered their target price on Biogen from $190.00 to $165.00 and set an "equal weight" rating on the stock in a research report on Friday, January 10th. Sixteen analysts have rated the stock with a hold rating and thirteen have issued a buy rating to the company. According to MarketBeat, the company currently has an average rating of "Hold" and a consensus target price of $228.80.
Check Out Our Latest Research Report on BIIB
Biogen Company Profile
(
Free Report)
Biogen Inc discovers, develops, manufactures, and delivers therapies for treating neurological and neurodegenerative diseases in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, TYSABRI, and FAMPYRA for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; ADUHELM to treat Alzheimer's disease; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE; and BYOOVIZ, a ranibizumab biosimilar referencing LUCENTIS.
Further Reading
Before you consider Biogen, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Biogen wasn't on the list.
While Biogen currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Just getting into the stock market? These 10 simple stocks can help beginning investors build long-term wealth without knowing options, technicals, or other advanced strategies.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
